nodes	percent_of_prediction	percent_of_DWPC	metapath
Dinoprostone—PTGER4—skin cancer	0.548	1	CbGaD
Dinoprostone—ABCC5—Fluorouracil—skin cancer	0.079	0.303	CbGbCtD
Dinoprostone—SLC22A7—Fluorouracil—skin cancer	0.0388	0.149	CbGbCtD
Dinoprostone—ABCC4—Fluorouracil—skin cancer	0.038	0.145	CbGbCtD
Dinoprostone—CYP1A2—Imiquimod—skin cancer	0.0342	0.131	CbGbCtD
Dinoprostone—SLC22A7—Docetaxel—skin cancer	0.0297	0.114	CbGbCtD
Dinoprostone—CYP1A2—Vemurafenib—skin cancer	0.0187	0.0717	CbGbCtD
Dinoprostone—CYP1A2—Dacarbazine—skin cancer	0.0144	0.055	CbGbCtD
Dinoprostone—Vulvitis—Imiquimod—skin cancer	0.01	0.125	CcSEcCtD
Dinoprostone—CYP1A2—Fluorouracil—skin cancer	0.00842	0.0322	CbGbCtD
Dinoprostone—Vulvovaginal pain—Imiquimod—skin cancer	0.00615	0.077	CcSEcCtD
Dinoprostone—Vaginal pain—Imiquimod—skin cancer	0.00615	0.077	CcSEcCtD
Dinoprostone—Misoprostol—PTGER4—skin cancer	0.00405	0.916	CrCbGaD
Dinoprostone—PTGIR—endothelium—skin cancer	0.00147	0.0343	CbGeAlD
Dinoprostone—Pregnancy—Imiquimod—skin cancer	0.00147	0.0184	CcSEcCtD
Dinoprostone—PTGIR—blood vessel—skin cancer	0.00136	0.0317	CbGeAlD
Dinoprostone—PTGER4—connective tissue—skin cancer	0.00117	0.0272	CbGeAlD
Dinoprostone—ABCC5—hair follicle—skin cancer	0.00116	0.027	CbGeAlD
Dinoprostone—PTGFR—nipple—skin cancer	0.00111	0.026	CbGeAlD
Dinoprostone—PTGER4—epithelium—skin cancer	0.00111	0.0258	CbGeAlD
Dinoprostone—Dehydration—Vismodegib—skin cancer	0.00107	0.0134	CcSEcCtD
Dinoprostone—PTGER3—connective tissue—skin cancer	0.000988	0.023	CbGeAlD
Dinoprostone—PTGER2—mammalian vulva—skin cancer	0.000979	0.0228	CbGeAlD
Dinoprostone—Disseminated intravascular coagulation—Docetaxel—skin cancer	0.000929	0.0116	CcSEcCtD
Dinoprostone—SLCO3A1—nipple—skin cancer	0.000867	0.0202	CbGeAlD
Dinoprostone—Inflammation—Imiquimod—skin cancer	0.000859	0.0107	CcSEcCtD
Dinoprostone—SLCO2A1—nipple—skin cancer	0.000858	0.02	CbGeAlD
Dinoprostone—HPGDS—connective tissue—skin cancer	0.000854	0.0199	CbGeAlD
Dinoprostone—PTGER4—lymphoid tissue—skin cancer	0.000853	0.0199	CbGeAlD
Dinoprostone—SLCO2A1—neck—skin cancer	0.000849	0.0198	CbGeAlD
Dinoprostone—PTGER2—female reproductive system—skin cancer	0.000839	0.0195	CbGeAlD
Dinoprostone—Vaginal inflammation—Imiquimod—skin cancer	0.000833	0.0104	CcSEcCtD
Dinoprostone—PTGER4—female reproductive system—skin cancer	0.000823	0.0192	CbGeAlD
Dinoprostone—HPGDS—epithelium—skin cancer	0.000811	0.0189	CbGeAlD
Dinoprostone—SLC51A—female reproductive system—skin cancer	0.000809	0.0188	CbGeAlD
Dinoprostone—PTGER1—female reproductive system—skin cancer	0.000795	0.0185	CbGeAlD
Dinoprostone—SLCO4A1—nipple—skin cancer	0.00079	0.0184	CbGeAlD
Dinoprostone—Vaginal infection—Imiquimod—skin cancer	0.000786	0.00984	CcSEcCtD
Dinoprostone—Chest tightness—Docetaxel—skin cancer	0.000708	0.00886	CcSEcCtD
Dinoprostone—HPGDS—mammalian vulva—skin cancer	0.000704	0.0164	CbGeAlD
Dinoprostone—PTGER3—female reproductive system—skin cancer	0.000697	0.0162	CbGeAlD
Dinoprostone—PTGIR—connective tissue—skin cancer	0.000696	0.0162	CbGeAlD
Dinoprostone—PTGER4—head—skin cancer	0.000688	0.016	CbGeAlD
Dinoprostone—SLC51A—head—skin cancer	0.000676	0.0157	CbGeAlD
Dinoprostone—Back pain—Vismodegib—skin cancer	0.000668	0.00836	CcSEcCtD
Dinoprostone—Muscle spasms—Vismodegib—skin cancer	0.000664	0.00831	CcSEcCtD
Dinoprostone—PTGER1—head—skin cancer	0.000664	0.0155	CbGeAlD
Dinoprostone—PTGIR—epithelium—skin cancer	0.000661	0.0154	CbGeAlD
Dinoprostone—HPGDS—lymphoid tissue—skin cancer	0.000625	0.0146	CbGeAlD
Dinoprostone—HPGDS—female reproductive system—skin cancer	0.000602	0.014	CbGeAlD
Dinoprostone—CYP11A1—connective tissue—skin cancer	0.000602	0.014	CbGeAlD
Dinoprostone—Myalgia—Vismodegib—skin cancer	0.000588	0.00736	CcSEcCtD
Dinoprostone—Arthralgia—Vismodegib—skin cancer	0.000588	0.00736	CcSEcCtD
Dinoprostone—PTGER3—head—skin cancer	0.000582	0.0136	CbGeAlD
Dinoprostone—SLCO2A1—epithelium—skin cancer	0.000578	0.0135	CbGeAlD
Dinoprostone—Urinary retention—Imiquimod—skin cancer	0.000575	0.00719	CcSEcCtD
Dinoprostone—Wheezing—Bleomycin—skin cancer	0.000575	0.00719	CcSEcCtD
Dinoprostone—PTGFR—female reproductive system—skin cancer	0.000557	0.013	CbGeAlD
Dinoprostone—SLCO2A1—skin of body—skin cancer	0.00055	0.0128	CbGeAlD
Dinoprostone—Hearing impaired—Temozolomide—skin cancer	0.000524	0.00656	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Vismodegib—skin cancer	0.000514	0.00643	CcSEcCtD
Dinoprostone—Sweating increased—Imiquimod—skin cancer	0.000509	0.00637	CcSEcCtD
Dinoprostone—SLCO3A1—mammalian vulva—skin cancer	0.000506	0.0118	CbGeAlD
Dinoprostone—HPGDS—head—skin cancer	0.000503	0.0117	CbGeAlD
Dinoprostone—SLCO2A1—mammalian vulva—skin cancer	0.000501	0.0117	CbGeAlD
Dinoprostone—Vaginal inflammation—Temozolomide—skin cancer	0.000499	0.00625	CcSEcCtD
Dinoprostone—PTGIR—female reproductive system—skin cancer	0.000491	0.0114	CbGeAlD
Dinoprostone—PTGER2—lymph node—skin cancer	0.000491	0.0114	CbGeAlD
Dinoprostone—Pain—Vismodegib—skin cancer	0.000482	0.00603	CcSEcCtD
Dinoprostone—PTGER4—lymph node—skin cancer	0.000482	0.0112	CbGeAlD
Dinoprostone—SLC22A11—female reproductive system—skin cancer	0.000479	0.0112	CbGeAlD
Dinoprostone—Inflammation—Fluorouracil—skin cancer	0.000474	0.00593	CcSEcCtD
Dinoprostone—SLC51A—lymph node—skin cancer	0.000473	0.011	CbGeAlD
Dinoprostone—Vaginal infection—Temozolomide—skin cancer	0.000471	0.0059	CcSEcCtD
Dinoprostone—PTGFR—head—skin cancer	0.000466	0.0109	CbGeAlD
Dinoprostone—Gastrointestinal pain—Vismodegib—skin cancer	0.000461	0.00577	CcSEcCtD
Dinoprostone—SLCO4A1—mammalian vulva—skin cancer	0.000461	0.0107	CbGeAlD
Dinoprostone—Acute coronary syndrome—Imiquimod—skin cancer	0.000459	0.00575	CcSEcCtD
Dinoprostone—Myocardial infarction—Imiquimod—skin cancer	0.000457	0.00571	CcSEcCtD
Dinoprostone—Abdominal pain—Vismodegib—skin cancer	0.000446	0.00558	CcSEcCtD
Dinoprostone—Angiopathy—Vemurafenib—skin cancer	0.000445	0.00557	CcSEcCtD
Dinoprostone—Chills—Vemurafenib—skin cancer	0.00044	0.00551	CcSEcCtD
Dinoprostone—SLCO3A1—female reproductive system—skin cancer	0.000433	0.0101	CbGeAlD
Dinoprostone—SLCO2A1—female reproductive system—skin cancer	0.000429	0.01	CbGeAlD
Dinoprostone—CYP11A1—female reproductive system—skin cancer	0.000425	0.0099	CbGeAlD
Dinoprostone—Pharyngitis—Imiquimod—skin cancer	0.000415	0.00519	CcSEcCtD
Dinoprostone—Back pain—Vemurafenib—skin cancer	0.000413	0.00517	CcSEcCtD
Dinoprostone—SLCO1C1—head—skin cancer	0.000412	0.0096	CbGeAlD
Dinoprostone—PTGIR—head—skin cancer	0.00041	0.00956	CbGeAlD
Dinoprostone—PTGER3—lymph node—skin cancer	0.000408	0.00951	CbGeAlD
Dinoprostone—Deafness—Temozolomide—skin cancer	0.000405	0.00507	CcSEcCtD
Dinoprostone—Asthenia—Vismodegib—skin cancer	0.000405	0.00506	CcSEcCtD
Dinoprostone—Eye pain—Temozolomide—skin cancer	0.000401	0.00502	CcSEcCtD
Dinoprostone—SLCO4A1—female reproductive system—skin cancer	0.000395	0.00921	CbGeAlD
Dinoprostone—CYP19A1—connective tissue—skin cancer	0.000391	0.00912	CbGeAlD
Dinoprostone—Flushing—Imiquimod—skin cancer	0.000388	0.00486	CcSEcCtD
Dinoprostone—Hot flush—Temozolomide—skin cancer	0.000387	0.00485	CcSEcCtD
Dinoprostone—Diarrhoea—Vismodegib—skin cancer	0.000386	0.00483	CcSEcCtD
Dinoprostone—Menopausal symptoms—Temozolomide—skin cancer	0.000384	0.0048	CcSEcCtD
Dinoprostone—Angiopathy—Imiquimod—skin cancer	0.000379	0.00475	CcSEcCtD
Dinoprostone—Immune system disorder—Imiquimod—skin cancer	0.000378	0.00473	CcSEcCtD
Dinoprostone—Chills—Imiquimod—skin cancer	0.000375	0.0047	CcSEcCtD
Dinoprostone—Chest discomfort—Docetaxel—skin cancer	0.000375	0.00469	CcSEcCtD
Dinoprostone—Arrhythmia—Imiquimod—skin cancer	0.000374	0.00468	CcSEcCtD
Dinoprostone—Dihomo-gamma-linolenic acid—PTGS2—skin cancer	0.000373	0.0843	CrCbGaD
Dinoprostone—Cough—Vemurafenib—skin cancer	0.000373	0.00466	CcSEcCtD
Dinoprostone—CYP1A2—nipple—skin cancer	0.00037	0.00862	CbGeAlD
Dinoprostone—Bronchospasm—Bleomycin—skin cancer	0.000365	0.00457	CcSEcCtD
Dinoprostone—Myalgia—Vemurafenib—skin cancer	0.000363	0.00455	CcSEcCtD
Dinoprostone—Arthralgia—Vemurafenib—skin cancer	0.000363	0.00455	CcSEcCtD
Dinoprostone—SLCO3A1—head—skin cancer	0.000362	0.00844	CbGeAlD
Dinoprostone—SLCO2A1—head—skin cancer	0.000359	0.00836	CbGeAlD
Dinoprostone—Vomiting—Vismodegib—skin cancer	0.000359	0.00449	CcSEcCtD
Dinoprostone—Rash—Vismodegib—skin cancer	0.000356	0.00445	CcSEcCtD
Dinoprostone—Dermatitis—Vismodegib—skin cancer	0.000355	0.00445	CcSEcCtD
Dinoprostone—CYP11A1—head—skin cancer	0.000355	0.00827	CbGeAlD
Dinoprostone—HPGDS—lymph node—skin cancer	0.000352	0.00822	CbGeAlD
Dinoprostone—Back pain—Imiquimod—skin cancer	0.000352	0.00441	CcSEcCtD
Dinoprostone—Hearing impaired—Docetaxel—skin cancer	0.000349	0.00436	CcSEcCtD
Dinoprostone—Anaphylactic shock—Vemurafenib—skin cancer	0.000348	0.00436	CcSEcCtD
Dinoprostone—SLCO1B1—female reproductive system—skin cancer	0.000347	0.0081	CbGeAlD
Dinoprostone—Inflammation—Docetaxel—skin cancer	0.000342	0.00428	CcSEcCtD
Dinoprostone—Dehydration—Temozolomide—skin cancer	0.000337	0.00422	CcSEcCtD
Dinoprostone—Nausea—Vismodegib—skin cancer	0.000335	0.00419	CcSEcCtD
Dinoprostone—SLCO4A1—head—skin cancer	0.00033	0.00769	CbGeAlD
Dinoprostone—Syncope—Imiquimod—skin cancer	0.000327	0.00409	CcSEcCtD
Dinoprostone—Acute coronary syndrome—Bleomycin—skin cancer	0.000326	0.00408	CcSEcCtD
Dinoprostone—PTGFR—lymph node—skin cancer	0.000326	0.0076	CbGeAlD
Dinoprostone—Hypotension—Vemurafenib—skin cancer	0.000326	0.00407	CcSEcCtD
Dinoprostone—Myocardial infarction—Bleomycin—skin cancer	0.000324	0.00406	CcSEcCtD
Dinoprostone—Loss of consciousness—Imiquimod—skin cancer	0.00032	0.004	CcSEcCtD
Dinoprostone—Cough—Imiquimod—skin cancer	0.000318	0.00398	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.000317	0.00397	CcSEcCtD
Dinoprostone—Cardiac arrest—Fluorouracil—skin cancer	0.000317	0.00397	CcSEcCtD
Dinoprostone—Hypertension—Imiquimod—skin cancer	0.000314	0.00393	CcSEcCtD
Dinoprostone—Chest pain—Imiquimod—skin cancer	0.00031	0.00388	CcSEcCtD
Dinoprostone—Arthralgia—Imiquimod—skin cancer	0.00031	0.00388	CcSEcCtD
Dinoprostone—Myalgia—Imiquimod—skin cancer	0.00031	0.00388	CcSEcCtD
Dinoprostone—SLCO2B1—female reproductive system—skin cancer	0.000307	0.00716	CbGeAlD
Dinoprostone—Sweating increased—Temozolomide—skin cancer	0.000305	0.00382	CcSEcCtD
Dinoprostone—Shock—Imiquimod—skin cancer	0.000292	0.00366	CcSEcCtD
Dinoprostone—Tachycardia—Imiquimod—skin cancer	0.00029	0.00363	CcSEcCtD
Dinoprostone—SLCO1C1—lymph node—skin cancer	0.000288	0.00672	CbGeAlD
Dinoprostone—PTGIR—lymph node—skin cancer	0.000287	0.0067	CbGeAlD
Dinoprostone—Hyperhidrosis—Imiquimod—skin cancer	0.000287	0.00359	CcSEcCtD
Dinoprostone—CYP19A1—female reproductive system—skin cancer	0.000276	0.00643	CbGeAlD
Dinoprostone—Flushing—Bleomycin—skin cancer	0.000276	0.00345	CcSEcCtD
Dinoprostone—Body temperature increased—Vemurafenib—skin cancer	0.000275	0.00345	CcSEcCtD
Dinoprostone—Pharyngitis—Dactinomycin—skin cancer	0.000275	0.00344	CcSEcCtD
Dinoprostone—ABCC4—female reproductive system—skin cancer	0.000272	0.00634	CbGeAlD
Dinoprostone—Musculoskeletal discomfort—Imiquimod—skin cancer	0.000271	0.00339	CcSEcCtD
Dinoprostone—Deafness—Docetaxel—skin cancer	0.000269	0.00337	CcSEcCtD
Dinoprostone—Paraesthesia—Imiquimod—skin cancer	0.000267	0.00334	CcSEcCtD
Dinoprostone—Chills—Bleomycin—skin cancer	0.000267	0.00334	CcSEcCtD
Dinoprostone—Dyspnoea—Imiquimod—skin cancer	0.000265	0.00331	CcSEcCtD
Dinoprostone—Hot flush—Docetaxel—skin cancer	0.000258	0.00322	CcSEcCtD
Dinoprostone—Flushing—Dactinomycin—skin cancer	0.000257	0.00322	CcSEcCtD
Dinoprostone—SLCO2B1—head—skin cancer	0.000257	0.00598	CbGeAlD
Dinoprostone—Hypersensitivity—Vemurafenib—skin cancer	0.000257	0.00321	CcSEcCtD
Dinoprostone—Menopausal symptoms—Docetaxel—skin cancer	0.000255	0.0032	CcSEcCtD
Dinoprostone—Pain—Imiquimod—skin cancer	0.000254	0.00318	CcSEcCtD
Dinoprostone—Acute coronary syndrome—Fluorouracil—skin cancer	0.000254	0.00317	CcSEcCtD
Dinoprostone—SLCO3A1—lymph node—skin cancer	0.000254	0.00591	CbGeAlD
Dinoprostone—Myocardial infarction—Fluorouracil—skin cancer	0.000252	0.00316	CcSEcCtD
Dinoprostone—SLCO2A1—lymph node—skin cancer	0.000251	0.00585	CbGeAlD
Dinoprostone—Asthenia—Vemurafenib—skin cancer	0.00025	0.00313	CcSEcCtD
Dinoprostone—Pharyngitis—Temozolomide—skin cancer	0.000249	0.00311	CcSEcCtD
Dinoprostone—Chills—Dactinomycin—skin cancer	0.000249	0.00311	CcSEcCtD
Dinoprostone—CYP11A1—lymph node—skin cancer	0.000248	0.00579	CbGeAlD
Dinoprostone—SLC22A1—head—skin cancer	0.000245	0.00572	CbGeAlD
Dinoprostone—Gastrointestinal pain—Imiquimod—skin cancer	0.000243	0.00304	CcSEcCtD
Dinoprostone—Diarrhoea—Vemurafenib—skin cancer	0.000238	0.00298	CcSEcCtD
Dinoprostone—SLCO1A2—head—skin cancer	0.000236	0.00551	CbGeAlD
Dinoprostone—Abdominal pain—Imiquimod—skin cancer	0.000235	0.00294	CcSEcCtD
Dinoprostone—Body temperature increased—Imiquimod—skin cancer	0.000235	0.00294	CcSEcCtD
Dinoprostone—Flushing—Temozolomide—skin cancer	0.000233	0.00291	CcSEcCtD
Dinoprostone—SLCO4A1—lymph node—skin cancer	0.000231	0.00538	CbGeAlD
Dinoprostone—CYP19A1—head—skin cancer	0.000231	0.00537	CbGeAlD
Dinoprostone—Dizziness—Vemurafenib—skin cancer	0.00023	0.00288	CcSEcCtD
Dinoprostone—ABCC5—lymph node—skin cancer	0.00023	0.00535	CbGeAlD
Dinoprostone—Pharyngitis—Fluorouracil—skin cancer	0.000229	0.00287	CcSEcCtD
Dinoprostone—Angiopathy—Temozolomide—skin cancer	0.000227	0.00285	CcSEcCtD
Dinoprostone—ABCC4—head—skin cancer	0.000227	0.0053	CbGeAlD
Dinoprostone—Immune system disorder—Temozolomide—skin cancer	0.000226	0.00283	CcSEcCtD
Dinoprostone—Cough—Bleomycin—skin cancer	0.000226	0.00282	CcSEcCtD
Dinoprostone—SLC22A8—head—skin cancer	0.000226	0.00526	CbGeAlD
Dinoprostone—Chills—Temozolomide—skin cancer	0.000225	0.00281	CcSEcCtD
Dinoprostone—Dehydration—Docetaxel—skin cancer	0.000224	0.0028	CcSEcCtD
Dinoprostone—Vomiting—Vemurafenib—skin cancer	0.000222	0.00277	CcSEcCtD
Dinoprostone—Chest pain—Bleomycin—skin cancer	0.00022	0.00276	CcSEcCtD
Dinoprostone—Myalgia—Bleomycin—skin cancer	0.00022	0.00276	CcSEcCtD
Dinoprostone—Rash—Vemurafenib—skin cancer	0.00022	0.00275	CcSEcCtD
Dinoprostone—Dermatitis—Vemurafenib—skin cancer	0.00022	0.00275	CcSEcCtD
Dinoprostone—Hypersensitivity—Imiquimod—skin cancer	0.000219	0.00274	CcSEcCtD
Dinoprostone—Headache—Vemurafenib—skin cancer	0.000218	0.00273	CcSEcCtD
Dinoprostone—Cramp muscle—Docetaxel—skin cancer	0.000217	0.00271	CcSEcCtD
Dinoprostone—Asthenia—Imiquimod—skin cancer	0.000213	0.00267	CcSEcCtD
Dinoprostone—Anaphylactic shock—Bleomycin—skin cancer	0.000211	0.00264	CcSEcCtD
Dinoprostone—Back pain—Temozolomide—skin cancer	0.000211	0.00264	CcSEcCtD
Dinoprostone—Nausea—Vemurafenib—skin cancer	0.000207	0.00259	CcSEcCtD
Dinoprostone—Arrhythmia—Fluorouracil—skin cancer	0.000206	0.00258	CcSEcCtD
Dinoprostone—Vision blurred—Temozolomide—skin cancer	0.000206	0.00257	CcSEcCtD
Dinoprostone—Myalgia—Dactinomycin—skin cancer	0.000205	0.00257	CcSEcCtD
Dinoprostone—Bronchospasm—Docetaxel—skin cancer	0.000205	0.00256	CcSEcCtD
Dinoprostone—Tremor—Temozolomide—skin cancer	0.000204	0.00256	CcSEcCtD
Dinoprostone—Diarrhoea—Imiquimod—skin cancer	0.000203	0.00254	CcSEcCtD
Dinoprostone—Hypotension—Bleomycin—skin cancer	0.000197	0.00247	CcSEcCtD
Dinoprostone—Dizziness—Imiquimod—skin cancer	0.000197	0.00246	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000192	0.00241	CcSEcCtD
Dinoprostone—Cough—Temozolomide—skin cancer	0.00019	0.00238	CcSEcCtD
Dinoprostone—Paraesthesia—Bleomycin—skin cancer	0.00019	0.00237	CcSEcCtD
Dinoprostone—Vision blurred—Fluorouracil—skin cancer	0.000189	0.00237	CcSEcCtD
Dinoprostone—Vomiting—Imiquimod—skin cancer	0.000189	0.00236	CcSEcCtD
Dinoprostone—Hypertension—Temozolomide—skin cancer	0.000188	0.00236	CcSEcCtD
Dinoprostone—Dyspnoea—Bleomycin—skin cancer	0.000188	0.00236	CcSEcCtD
Dinoprostone—Rash—Imiquimod—skin cancer	0.000187	0.00234	CcSEcCtD
Dinoprostone—Dermatitis—Imiquimod—skin cancer	0.000187	0.00234	CcSEcCtD
Dinoprostone—Headache—Imiquimod—skin cancer	0.000186	0.00233	CcSEcCtD
Dinoprostone—Arthralgia—Temozolomide—skin cancer	0.000186	0.00232	CcSEcCtD
Dinoprostone—Myalgia—Temozolomide—skin cancer	0.000186	0.00232	CcSEcCtD
Dinoprostone—Acute coronary syndrome—Docetaxel—skin cancer	0.000183	0.00229	CcSEcCtD
Dinoprostone—Myocardial infarction—Docetaxel—skin cancer	0.000182	0.00228	CcSEcCtD
Dinoprostone—Pain—Bleomycin—skin cancer	0.000181	0.00226	CcSEcCtD
Dinoprostone—SLCO2B1—lymph node—skin cancer	0.00018	0.00419	CbGeAlD
Dinoprostone—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000179	0.00224	CcSEcCtD
Dinoprostone—Anaphylactic shock—Temozolomide—skin cancer	0.000178	0.00223	CcSEcCtD
Dinoprostone—Nausea—Imiquimod—skin cancer	0.000177	0.00221	CcSEcCtD
Dinoprostone—Hyperhidrosis—Temozolomide—skin cancer	0.000172	0.00215	CcSEcCtD
Dinoprostone—Chest pain—Fluorouracil—skin cancer	0.000171	0.00214	CcSEcCtD
Dinoprostone—Myalgia—Fluorouracil—skin cancer	0.000171	0.00214	CcSEcCtD
Dinoprostone—Pain—Dactinomycin—skin cancer	0.000168	0.00211	CcSEcCtD
Dinoprostone—Body temperature increased—Bleomycin—skin cancer	0.000167	0.00209	CcSEcCtD
Dinoprostone—Pharyngitis—Docetaxel—skin cancer	0.000165	0.00207	CcSEcCtD
Dinoprostone—Anaphylactic shock—Fluorouracil—skin cancer	0.000164	0.00205	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000162	0.00203	CcSEcCtD
Dinoprostone—CYP19A1—lymph node—skin cancer	0.000161	0.00376	CbGeAlD
Dinoprostone—Gastrointestinal pain—Dactinomycin—skin cancer	0.000161	0.00201	CcSEcCtD
Dinoprostone—Tachycardia—Fluorouracil—skin cancer	0.00016	0.002	CcSEcCtD
Dinoprostone—Paraesthesia—Temozolomide—skin cancer	0.00016	0.002	CcSEcCtD
Dinoprostone—ABCC4—lymph node—skin cancer	0.000159	0.00371	CbGeAlD
Dinoprostone—Dyspnoea—Temozolomide—skin cancer	0.000159	0.00199	CcSEcCtD
Dinoprostone—Abdominal pain—Dactinomycin—skin cancer	0.000156	0.00195	CcSEcCtD
Dinoprostone—Body temperature increased—Dactinomycin—skin cancer	0.000156	0.00195	CcSEcCtD
Dinoprostone—Hypersensitivity—Bleomycin—skin cancer	0.000156	0.00195	CcSEcCtD
Dinoprostone—Flushing—Docetaxel—skin cancer	0.000155	0.00194	CcSEcCtD
Dinoprostone—Hypotension—Fluorouracil—skin cancer	0.000153	0.00192	CcSEcCtD
Dinoprostone—Pain—Temozolomide—skin cancer	0.000152	0.00191	CcSEcCtD
Dinoprostone—Asthenia—Bleomycin—skin cancer	0.000151	0.0019	CcSEcCtD
Dinoprostone—Angiopathy—Docetaxel—skin cancer	0.000151	0.00189	CcSEcCtD
Dinoprostone—Immune system disorder—Docetaxel—skin cancer	0.000151	0.00188	CcSEcCtD
Dinoprostone—Chills—Docetaxel—skin cancer	0.00015	0.00187	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000149	0.00187	CcSEcCtD
Dinoprostone—Arrhythmia—Docetaxel—skin cancer	0.000149	0.00186	CcSEcCtD
Dinoprostone—Paraesthesia—Fluorouracil—skin cancer	0.000147	0.00184	CcSEcCtD
Dinoprostone—Dyspnoea—Fluorouracil—skin cancer	0.000146	0.00183	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Temozolomide—skin cancer	0.000146	0.00182	CcSEcCtD
Dinoprostone—Hypersensitivity—Dactinomycin—skin cancer	0.000145	0.00182	CcSEcCtD
Dinoprostone—Asthenia—Dactinomycin—skin cancer	0.000141	0.00177	CcSEcCtD
Dinoprostone—Abdominal pain—Temozolomide—skin cancer	0.000141	0.00176	CcSEcCtD
Dinoprostone—Body temperature increased—Temozolomide—skin cancer	0.000141	0.00176	CcSEcCtD
Dinoprostone—Back pain—Docetaxel—skin cancer	0.00014	0.00176	CcSEcCtD
Dinoprostone—Pain—Fluorouracil—skin cancer	0.00014	0.00176	CcSEcCtD
Dinoprostone—Muscle spasms—Docetaxel—skin cancer	0.00014	0.00175	CcSEcCtD
Dinoprostone—Diarrhoea—Dactinomycin—skin cancer	0.000135	0.00169	CcSEcCtD
Dinoprostone—Vomiting—Bleomycin—skin cancer	0.000134	0.00168	CcSEcCtD
Dinoprostone—Rash—Bleomycin—skin cancer	0.000133	0.00167	CcSEcCtD
Dinoprostone—Dermatitis—Bleomycin—skin cancer	0.000133	0.00166	CcSEcCtD
Dinoprostone—Hypersensitivity—Temozolomide—skin cancer	0.000131	0.00164	CcSEcCtD
Dinoprostone—Syncope—Docetaxel—skin cancer	0.00013	0.00163	CcSEcCtD
Dinoprostone—Body temperature increased—Fluorouracil—skin cancer	0.00013	0.00162	CcSEcCtD
Dinoprostone—Asthenia—Temozolomide—skin cancer	0.000128	0.0016	CcSEcCtD
Dinoprostone—Loss of consciousness—Docetaxel—skin cancer	0.000128	0.0016	CcSEcCtD
Dinoprostone—Cough—Docetaxel—skin cancer	0.000127	0.00158	CcSEcCtD
Dinoprostone—Nausea—Bleomycin—skin cancer	0.000125	0.00157	CcSEcCtD
Dinoprostone—Hypertension—Docetaxel—skin cancer	0.000125	0.00157	CcSEcCtD
Dinoprostone—Vomiting—Dactinomycin—skin cancer	0.000125	0.00157	CcSEcCtD
Dinoprostone—Rash—Dactinomycin—skin cancer	0.000124	0.00155	CcSEcCtD
Dinoprostone—Chest pain—Docetaxel—skin cancer	0.000124	0.00155	CcSEcCtD
Dinoprostone—Arthralgia—Docetaxel—skin cancer	0.000124	0.00155	CcSEcCtD
Dinoprostone—Myalgia—Docetaxel—skin cancer	0.000124	0.00155	CcSEcCtD
Dinoprostone—Diarrhoea—Temozolomide—skin cancer	0.000122	0.00152	CcSEcCtD
Dinoprostone—Hypersensitivity—Fluorouracil—skin cancer	0.000121	0.00151	CcSEcCtD
Dinoprostone—Anaphylactic shock—Docetaxel—skin cancer	0.000118	0.00148	CcSEcCtD
Dinoprostone—Dizziness—Temozolomide—skin cancer	0.000118	0.00147	CcSEcCtD
Dinoprostone—Nausea—Dactinomycin—skin cancer	0.000117	0.00146	CcSEcCtD
Dinoprostone—Shock—Docetaxel—skin cancer	0.000117	0.00146	CcSEcCtD
Dinoprostone—Tachycardia—Docetaxel—skin cancer	0.000116	0.00145	CcSEcCtD
Dinoprostone—Vomiting—Temozolomide—skin cancer	0.000113	0.00142	CcSEcCtD
Dinoprostone—Rash—Temozolomide—skin cancer	0.000112	0.0014	CcSEcCtD
Dinoprostone—Diarrhoea—Fluorouracil—skin cancer	0.000112	0.0014	CcSEcCtD
Dinoprostone—Dermatitis—Temozolomide—skin cancer	0.000112	0.0014	CcSEcCtD
Dinoprostone—Headache—Temozolomide—skin cancer	0.000112	0.0014	CcSEcCtD
Dinoprostone—Hypotension—Docetaxel—skin cancer	0.000111	0.00138	CcSEcCtD
Dinoprostone—Dizziness—Fluorouracil—skin cancer	0.000109	0.00136	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000108	0.00135	CcSEcCtD
Dinoprostone—Paraesthesia—Docetaxel—skin cancer	0.000106	0.00133	CcSEcCtD
Dinoprostone—Nausea—Temozolomide—skin cancer	0.000106	0.00132	CcSEcCtD
Dinoprostone—Dyspnoea—Docetaxel—skin cancer	0.000106	0.00132	CcSEcCtD
Dinoprostone—Vomiting—Fluorouracil—skin cancer	0.000104	0.00131	CcSEcCtD
Dinoprostone—Rash—Fluorouracil—skin cancer	0.000103	0.00129	CcSEcCtD
Dinoprostone—Dermatitis—Fluorouracil—skin cancer	0.000103	0.00129	CcSEcCtD
Dinoprostone—Headache—Fluorouracil—skin cancer	0.000103	0.00129	CcSEcCtD
Dinoprostone—Pain—Docetaxel—skin cancer	0.000101	0.00127	CcSEcCtD
Dinoprostone—Nausea—Fluorouracil—skin cancer	9.75e-05	0.00122	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Docetaxel—skin cancer	9.68e-05	0.00121	CcSEcCtD
Dinoprostone—Abdominal pain—Docetaxel—skin cancer	9.36e-05	0.00117	CcSEcCtD
Dinoprostone—Body temperature increased—Docetaxel—skin cancer	9.36e-05	0.00117	CcSEcCtD
Dinoprostone—Hypersensitivity—Docetaxel—skin cancer	8.73e-05	0.00109	CcSEcCtD
Dinoprostone—Asthenia—Docetaxel—skin cancer	8.5e-05	0.00106	CcSEcCtD
Dinoprostone—Diarrhoea—Docetaxel—skin cancer	8.1e-05	0.00101	CcSEcCtD
Dinoprostone—Dizziness—Docetaxel—skin cancer	7.83e-05	0.00098	CcSEcCtD
Dinoprostone—Vomiting—Docetaxel—skin cancer	7.53e-05	0.000942	CcSEcCtD
Dinoprostone—Rash—Docetaxel—skin cancer	7.47e-05	0.000934	CcSEcCtD
Dinoprostone—Dermatitis—Docetaxel—skin cancer	7.46e-05	0.000933	CcSEcCtD
Dinoprostone—Headache—Docetaxel—skin cancer	7.42e-05	0.000928	CcSEcCtD
Dinoprostone—Nausea—Docetaxel—skin cancer	7.03e-05	0.00088	CcSEcCtD
Dinoprostone—PTGER1—Signaling by GPCR—MC1R—skin cancer	6.11e-05	0.000959	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling by GPCR—PTCH1—skin cancer	6.11e-05	0.000959	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling by GPCR—SMO—skin cancer	6.11e-05	0.000959	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—SUFU—skin cancer	6.08e-05	0.000954	CbGpPWpGaD
Dinoprostone—PTGER3—GPCR downstream signaling—PTGER4—skin cancer	6.05e-05	0.000949	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	5.95e-05	0.000934	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling by GPCR—PTGER4—skin cancer	5.95e-05	0.000933	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling by GPCR—SHH—skin cancer	5.95e-05	0.000933	CbGpPWpGaD
Dinoprostone—SLC22A6—Transmembrane transport of small molecules—SLC12A2—skin cancer	5.9e-05	0.000925	CbGpPWpGaD
Dinoprostone—HPGDS—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	5.7e-05	0.000894	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling by GPCR—PTCH1—skin cancer	5.64e-05	0.000885	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling by GPCR—SMO—skin cancer	5.64e-05	0.000885	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—GLI2—skin cancer	5.6e-05	0.000879	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling by GPCR—PTGER4—skin cancer	5.49e-05	0.000861	CbGpPWpGaD
Dinoprostone—SLCO1B1—Transmembrane transport of small molecules—SLC12A2—skin cancer	5.37e-05	0.000842	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—MC1R—skin cancer	5.35e-05	0.000838	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—GLI1—skin cancer	5.27e-05	0.000826	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—GLI2—skin cancer	5.17e-05	0.000811	CbGpPWpGaD
Dinoprostone—HPGDS—Metabolism—ENO2—skin cancer	5.11e-05	0.000802	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—PTCH2—skin cancer	5.1e-05	0.0008	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—PTCH2—skin cancer	4.99e-05	0.000783	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—SUFU—skin cancer	4.99e-05	0.000783	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—PTCH2—skin cancer	4.99e-05	0.000783	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—MC1R—skin cancer	4.93e-05	0.000774	CbGpPWpGaD
Dinoprostone—SLC22A2—Transmembrane transport of small molecules—SLC12A2—skin cancer	4.92e-05	0.000771	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—GLI1—skin cancer	4.86e-05	0.000763	CbGpPWpGaD
Dinoprostone—CYP19A1—Integrated Breast Cancer Pathway—CDK4—skin cancer	4.85e-05	0.000762	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—PLIN2—skin cancer	4.83e-05	0.000757	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—CSPG4—skin cancer	4.65e-05	0.000729	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—SHH—skin cancer	4.64e-05	0.000728	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—RASA1—skin cancer	4.61e-05	0.000723	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—SUFU—skin cancer	4.61e-05	0.000723	CbGpPWpGaD
Dinoprostone—SLC22A1—Transmembrane transport of small molecules—SLC12A2—skin cancer	4.58e-05	0.000719	CbGpPWpGaD
Dinoprostone—PTGFR—GPCR downstream signaling—PTGER4—skin cancer	4.52e-05	0.000709	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—SHH—skin cancer	4.45e-05	0.000698	CbGpPWpGaD
Dinoprostone—PTGIR—GPCR downstream signaling—PTGER4—skin cancer	4.43e-05	0.000694	CbGpPWpGaD
Dinoprostone—PTGER1—GPCR downstream signaling—PTGER4—skin cancer	4.43e-05	0.000694	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—PTCH1—skin cancer	4.4e-05	0.00069	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—SMO—skin cancer	4.4e-05	0.00069	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—SHH—skin cancer	4.36e-05	0.000683	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—SHH—skin cancer	4.36e-05	0.000683	CbGpPWpGaD
Dinoprostone—CYP19A1—Integrated Breast Cancer Pathway—BRAF—skin cancer	4.3e-05	0.000674	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—PLIN2—skin cancer	4.23e-05	0.000663	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—PTCH1—skin cancer	4.22e-05	0.000662	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—SMO—skin cancer	4.22e-05	0.000662	CbGpPWpGaD
Dinoprostone—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	4.17e-05	0.000654	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—SMO—skin cancer	4.13e-05	0.000648	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—PTCH1—skin cancer	4.13e-05	0.000648	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—SMO—skin cancer	4.13e-05	0.000648	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—PTCH1—skin cancer	4.13e-05	0.000648	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—PTGER4—skin cancer	4.11e-05	0.000644	CbGpPWpGaD
Dinoprostone—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	4.08e-05	0.00064	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—PTGER4—skin cancer	4.02e-05	0.00063	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—PTGER4—skin cancer	4.02e-05	0.00063	CbGpPWpGaD
Dinoprostone—HPGDS—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	4e-05	0.000627	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—CSPG4—skin cancer	3.89e-05	0.000611	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—GLI2—skin cancer	3.87e-05	0.000607	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—SHH—skin cancer	3.81e-05	0.000597	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—GLI2—skin cancer	3.79e-05	0.000594	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—GLI2—skin cancer	3.79e-05	0.000594	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—RASA1—skin cancer	3.79e-05	0.000594	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—FOXO4—skin cancer	3.78e-05	0.000593	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—MC1R—skin cancer	3.69e-05	0.000579	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—GLI1—skin cancer	3.64e-05	0.00057	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—MC1R—skin cancer	3.61e-05	0.000566	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—MC1R—skin cancer	3.61e-05	0.000566	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—PTCH1—skin cancer	3.61e-05	0.000566	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—SMO—skin cancer	3.61e-05	0.000566	CbGpPWpGaD
Dinoprostone—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	3.59e-05	0.000563	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—GLI1—skin cancer	3.56e-05	0.000558	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—GLI1—skin cancer	3.56e-05	0.000558	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—SHH—skin cancer	3.52e-05	0.000551	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—PTGER4—skin cancer	3.52e-05	0.000551	CbGpPWpGaD
Dinoprostone—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	3.51e-05	0.000551	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—RASA1—skin cancer	3.49e-05	0.000548	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—SUFU—skin cancer	3.45e-05	0.000541	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—CSPG4—skin cancer	3.41e-05	0.000535	CbGpPWpGaD
Dinoprostone—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—skin cancer	3.4e-05	0.000533	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—SUFU—skin cancer	3.37e-05	0.000529	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—SUFU—skin cancer	3.37e-05	0.000529	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—PTCH1—skin cancer	3.33e-05	0.000523	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—SMO—skin cancer	3.33e-05	0.000523	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—PTGER4—skin cancer	3.24e-05	0.000509	CbGpPWpGaD
Dinoprostone—CYP1A2—Arachidonic acid metabolism—PTGS2—skin cancer	3.18e-05	0.000498	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—ENO2—skin cancer	3.16e-05	0.000496	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—SHH—skin cancer	3.16e-05	0.000496	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—FOXO4—skin cancer	3.11e-05	0.000487	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—PLIN2—skin cancer	3.1e-05	0.000486	CbGpPWpGaD
Dinoprostone—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	3.05e-05	0.000478	CbGpPWpGaD
Dinoprostone—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	2.98e-05	0.000468	CbGpPWpGaD
Dinoprostone—SLC22A2—Transmission across Chemical Synapses—BRAF—skin cancer	2.97e-05	0.000467	CbGpPWpGaD
Dinoprostone—HPGDS—Metabolism—ERCC2—skin cancer	2.97e-05	0.000466	CbGpPWpGaD
Dinoprostone—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	2.92e-05	0.000458	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—FOXO4—skin cancer	2.87e-05	0.000449	CbGpPWpGaD
Dinoprostone—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	2.86e-05	0.000448	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—PLIN2—skin cancer	2.8e-05	0.000439	CbGpPWpGaD
Dinoprostone—SLC22A1—Transmission across Chemical Synapses—BRAF—skin cancer	2.77e-05	0.000435	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—PLIN2—skin cancer	2.65e-05	0.000416	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—ENO2—skin cancer	2.65e-05	0.000415	CbGpPWpGaD
Dinoprostone—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—skin cancer	2.64e-05	0.000414	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—SHH—skin cancer	2.63e-05	0.000412	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—RASA1—skin cancer	2.61e-05	0.00041	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—FOXO4—skin cancer	2.58e-05	0.000404	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—SHH—skin cancer	2.57e-05	0.000404	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—SHH—skin cancer	2.57e-05	0.000404	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—RASA1—skin cancer	2.56e-05	0.000401	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—RASA1—skin cancer	2.56e-05	0.000401	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—TERT—skin cancer	2.53e-05	0.000396	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—CSPG4—skin cancer	2.5e-05	0.000392	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—PTCH1—skin cancer	2.49e-05	0.000391	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—SMO—skin cancer	2.49e-05	0.000391	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—SMO—skin cancer	2.44e-05	0.000383	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—SMO—skin cancer	2.44e-05	0.000383	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—PTCH1—skin cancer	2.44e-05	0.000383	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—PTCH1—skin cancer	2.44e-05	0.000383	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—PLIN2—skin cancer	2.43e-05	0.000381	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—PTGER4—skin cancer	2.43e-05	0.00038	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	2.38e-05	0.000373	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—PTGER4—skin cancer	2.37e-05	0.000372	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—PTGER4—skin cancer	2.37e-05	0.000372	CbGpPWpGaD
Dinoprostone—CYP19A1—Integrated Breast Cancer Pathway—KRAS—skin cancer	2.32e-05	0.000364	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—ENO2—skin cancer	2.32e-05	0.000364	CbGpPWpGaD
Dinoprostone—SLC22A2—Neuronal System—BRAF—skin cancer	2.28e-05	0.000357	CbGpPWpGaD
Dinoprostone—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—skin cancer	2.27e-05	0.000357	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—PLIN2—skin cancer	2.26e-05	0.000355	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—CSPG4—skin cancer	2.26e-05	0.000354	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—FOXO4—skin cancer	2.14e-05	0.000336	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—CSPG4—skin cancer	2.14e-05	0.000335	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling by GPCR—NRAS—skin cancer	2.13e-05	0.000334	CbGpPWpGaD
Dinoprostone—SLC22A1—Neuronal System—BRAF—skin cancer	2.12e-05	0.000333	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—FOXO4—skin cancer	2.1e-05	0.000329	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—FOXO4—skin cancer	2.1e-05	0.000329	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—TERT—skin cancer	2.07e-05	0.000325	CbGpPWpGaD
Dinoprostone—CYP19A1—Integrated Breast Cancer Pathway—TP53—skin cancer	2.07e-05	0.000324	CbGpPWpGaD
Dinoprostone—PTGIR—Hemostasis—NRAS—skin cancer	2.06e-05	0.000323	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—BRAF—skin cancer	2e-05	0.000314	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—CSPG4—skin cancer	1.96e-05	0.000307	CbGpPWpGaD
Dinoprostone—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—skin cancer	1.93e-05	0.000303	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—TERT—skin cancer	1.91e-05	0.0003	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—ERCC2—skin cancer	1.84e-05	0.000288	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling by GPCR—KRAS—skin cancer	1.83e-05	0.000287	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—CSPG4—skin cancer	1.83e-05	0.000286	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.81e-05	0.000284	CbGpPWpGaD
Dinoprostone—HPGDS—Metabolism—PTGS2—skin cancer	1.78e-05	0.000279	CbGpPWpGaD
Dinoprostone—PTGIR—Hemostasis—KRAS—skin cancer	1.77e-05	0.000278	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling by GPCR—NRAS—skin cancer	1.75e-05	0.000274	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—TERT—skin cancer	1.72e-05	0.00027	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—ENO2—skin cancer	1.7e-05	0.000266	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—BRAF—skin cancer	1.64e-05	0.000258	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling by GPCR—NRAS—skin cancer	1.61e-05	0.000253	CbGpPWpGaD
Dinoprostone—PTGIR—Hemostasis—TP53—skin cancer	1.57e-05	0.000247	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling by GPCR—HRAS—skin cancer	1.56e-05	0.000244	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—ERCC2—skin cancer	1.54e-05	0.000241	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—ENO2—skin cancer	1.54e-05	0.000241	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—BRAF—skin cancer	1.52e-05	0.000238	CbGpPWpGaD
Dinoprostone—PTGIR—Hemostasis—HRAS—skin cancer	1.5e-05	0.000236	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling by GPCR—KRAS—skin cancer	1.5e-05	0.000236	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling by GPCR—IL6—skin cancer	1.49e-05	0.000234	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—ENO2—skin cancer	1.45e-05	0.000228	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—TERT—skin cancer	1.43e-05	0.000224	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—TERT—skin cancer	1.4e-05	0.00022	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—TERT—skin cancer	1.4e-05	0.00022	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling by GPCR—KRAS—skin cancer	1.39e-05	0.000218	CbGpPWpGaD
Dinoprostone—SLC22A2—Transmission across Chemical Synapses—HRAS—skin cancer	1.37e-05	0.000215	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—BRAF—skin cancer	1.36e-05	0.000214	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—ERCC2—skin cancer	1.35e-05	0.000211	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—ENO2—skin cancer	1.33e-05	0.000209	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.33e-05	0.000208	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling by GPCR—HRAS—skin cancer	1.28e-05	0.000201	CbGpPWpGaD
Dinoprostone—SLC22A1—Transmission across Chemical Synapses—HRAS—skin cancer	1.27e-05	0.0002	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—NRAS—skin cancer	1.26e-05	0.000197	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—ENO2—skin cancer	1.24e-05	0.000195	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—NRAS—skin cancer	1.23e-05	0.000192	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling by GPCR—IL6—skin cancer	1.22e-05	0.000192	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—NRAS—skin cancer	1.21e-05	0.000189	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.2e-05	0.000188	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—NRAS—skin cancer	1.18e-05	0.000185	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—NRAS—skin cancer	1.18e-05	0.000185	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling by GPCR—HRAS—skin cancer	1.18e-05	0.000185	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.14e-05	0.000178	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—BRAF—skin cancer	1.13e-05	0.000178	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling by GPCR—IL6—skin cancer	1.13e-05	0.000177	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—BRAF—skin cancer	1.11e-05	0.000174	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—BRAF—skin cancer	1.11e-05	0.000174	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—PTGS2—skin cancer	1.1e-05	0.000173	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—KRAS—skin cancer	1.08e-05	0.00017	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—PLIN2—skin cancer	1.06e-05	0.000166	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—KRAS—skin cancer	1.06e-05	0.000165	CbGpPWpGaD
Dinoprostone—SLC22A2—Neuronal System—HRAS—skin cancer	1.05e-05	0.000164	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—KRAS—skin cancer	1.04e-05	0.000163	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—NRAS—skin cancer	1.03e-05	0.000162	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—KRAS—skin cancer	1.02e-05	0.000159	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—KRAS—skin cancer	1.02e-05	0.000159	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—ERCC2—skin cancer	9.87e-06	0.000155	CbGpPWpGaD
Dinoprostone—SLC22A1—Neuronal System—HRAS—skin cancer	9.77e-06	0.000153	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—TP53—skin cancer	9.62e-06	0.000151	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—NRAS—skin cancer	9.53e-06	0.000149	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—TP53—skin cancer	9.38e-06	0.000147	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—PTGS2—skin cancer	9.22e-06	0.000145	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—HRAS—skin cancer	9.2e-06	0.000144	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—HRAS—skin cancer	8.97e-06	0.000141	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—ERCC2—skin cancer	8.92e-06	0.00014	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—KRAS—skin cancer	8.88e-06	0.000139	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—HRAS—skin cancer	8.82e-06	0.000138	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—IL6—skin cancer	8.8e-06	0.000138	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—HRAS—skin cancer	8.63e-06	0.000135	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—HRAS—skin cancer	8.63e-06	0.000135	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—NRAS—skin cancer	8.56e-06	0.000134	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—CSPG4—skin cancer	8.54e-06	0.000134	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—IL6—skin cancer	8.44e-06	0.000132	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—ERCC2—skin cancer	8.44e-06	0.000132	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—IL6—skin cancer	8.26e-06	0.00013	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—IL6—skin cancer	8.26e-06	0.00013	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—KRAS—skin cancer	8.2e-06	0.000129	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—PTGS2—skin cancer	8.07e-06	0.000127	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—TP53—skin cancer	7.9e-06	0.000124	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—ERCC2—skin cancer	7.73e-06	0.000121	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—HRAS—skin cancer	7.55e-06	0.000118	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—KRAS—skin cancer	7.37e-06	0.000116	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—TP53—skin cancer	7.29e-06	0.000114	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—IL6—skin cancer	7.23e-06	0.000113	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—ERCC2—skin cancer	7.21e-06	0.000113	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—NRAS—skin cancer	7.12e-06	0.000112	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—NRAS—skin cancer	6.97e-06	0.000109	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—NRAS—skin cancer	6.97e-06	0.000109	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—HRAS—skin cancer	6.97e-06	0.000109	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—IL6—skin cancer	6.67e-06	0.000105	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—HRAS—skin cancer	6.26e-06	9.82e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—KRAS—skin cancer	6.13e-06	9.62e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—KRAS—skin cancer	6e-06	9.41e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—KRAS—skin cancer	6e-06	9.41e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—IL6—skin cancer	5.99e-06	9.4e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—PTGS2—skin cancer	5.92e-06	9.28e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—ENO2—skin cancer	5.8e-06	9.11e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—TP53—skin cancer	5.45e-06	8.55e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—PTGS2—skin cancer	5.35e-06	8.39e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—TP53—skin cancer	5.33e-06	8.37e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—TP53—skin cancer	5.33e-06	8.37e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—HRAS—skin cancer	5.21e-06	8.17e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—HRAS—skin cancer	5.1e-06	8e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—HRAS—skin cancer	5.1e-06	8e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—PTGS2—skin cancer	5.06e-06	7.94e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—IL6—skin cancer	4.99e-06	7.82e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—IL6—skin cancer	4.88e-06	7.66e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—IL6—skin cancer	4.88e-06	7.66e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—PTGS2—skin cancer	4.64e-06	7.27e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	4.54e-06	7.12e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—PTGS2—skin cancer	4.32e-06	6.78e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—ERCC2—skin cancer	3.37e-06	5.29e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—PTGS2—skin cancer	2.02e-06	3.17e-05	CbGpPWpGaD
